A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Ponatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms POSEIDON
- Sponsors Incyte Biosciences International
- 12 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to revisiting the availability of patients with Ph+ ALL that would meet the in-/exclusion criteria of the study led to the decision not to move forward
- 30 Nov 2018 Planned initiation date changed from 15 Nov 2018 to 31 Dec 2018.
- 03 Oct 2018 Planned initiation date changed from 15 Sep 2018 to 15 Nov 2018.